Hospital volume is associated with survival but not multimodality therapy in Medicare patients with advanced head and neck cancer

Cancer

Volumn 119, Issue 10, 2013, Pages 1845-1852

  Sharma, Arun ^a   Schwartz, Stephen M ^a,b   Méndez, Eduardo ^a,b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

chemoradiotherapy; cisplatin; head and neck neoplasms; radiotherapy; survival

Indexed keywords

CISPLATIN;

ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEALTH SURVEY; HOSPITAL; HOSPITAL SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEDICARE; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE; SOCIAL STATUS; SURVIVAL;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; HEAD AND NECK NEOPLASMS; HOSPITALS, HIGH-VOLUME; HOSPITALS, LOW-VOLUME; HUMANS; INTERDISCIPLINARY COMMUNICATION; KAPLAN-MEIER ESTIMATE; MALE; MEDICARE; MULTIVARIATE ANALYSIS; ODDS RATIO; ONCOLOGY SERVICE, HOSPITAL; PATIENT CARE TEAM; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SEER PROGRAM; TREATMENT OUTCOME; UNITED STATES;

EID: 84877575236     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27976     Document Type: Article

References (29)

1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society; 2012.
2. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP,. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer. 2005; 114: 806-816.
3. Wong RJ, Shah JP,. The role of the head and neck surgeon in contemporary multidisciplinary treatment programs for advanced head and neck cancer. Curr Opin Otolaryngol Head Neck Surg. 2010; 18: 79-82.
4. National Comprehensive Cancer Network. NCCN Guidelines for head and neck cancer care. http://www.nccn.org/professionals/physician-gls/PDF/head-and-neck. pdf. Accessed July 22, 2010.
5. Bachaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano E, Daly-Schveitzer N,. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys. 1996; 36: 999-1004.
6. Wendt TG, Grabenbauer GG, Rödel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998; 16: 1318-1324.
7. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349: 2091-2098.
8. Bernier J, Domenge C, Ozsahin M, et al. European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350: 1945-1952.
9. Cooper JS, Pajak TF, Forastiere AA, et al. Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004; 350: 1937-1944.
10. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005; 27: 843-850.
11. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008; 26: 3582-3589.
12. Begg CB, Cramer LD, Hoskins WJ, Brennan MF,. Impact of hospital volume on operative mortality for major cancer surgery. JAMA. 1998; 280: 1747-1751.
13. Chen YK, Lin HC,. Association between urologists' caseload volume and in-hospital mortality for transurethral resection of prostate: a nationwide population-based study. Urology. 2008; 72: 329-335.
14. Chen AY, Fedewa S, Pavluck A, Ward EM,. Improved survival is associated with treatment at high-volume teaching facilities for patients with advanced stage laryngeal cancer. Cancer. 2010; 116: 4744-4752.
15. Chen AY, Pavluck A, Halpern M, Ward E,. Impact of treating facilities' volume on survival for early-stage laryngeal cancer. Head Neck. 2009; 31: 1137-1143.
16. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF,. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40 (8 suppl): IV-3-18.
17. Hankey BF, Ries LA, Edwards BK,. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999; 8: 1117-1121.
18. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL,. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002; 40 (8 suppl): IV-19-25.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
20. Deyo RA, Cherkin DC, Ciol MA,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613-619.
21. Klabunde CN, Potosky AL, Legler JM, Warren JL,. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267.
22. Panageas KS, Schrag D, Riedel E, Bach PB, Begg CB,. The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med. 2003; 139: 658-665.
23. Liang KY, Zeger SL,. Regression analysis for correlated data. Annu Rev Public Health. 1993; 14: 43-68.
24. Andersen PK, Klein JP, Knudsen KM, Tabanera y Palacios R,. Estimation of variance in Cox's regression model with shared gamma frailties. Biometrics. 1997; 53: 1475-1484.
25. Corrêa GT, Bandeira GA, Cavalcanti BG, et al. Analysis of ECOG performance status in head and neck squamous cell carcinoma patients: association with sociodemographical and clinical factors, and overall survival. Support Care Cancer. 2012; 20: 2679-2685.
26. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr,. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004; 291: 2441-2447.
27. Bach PB, Cramer LD, Schrag D, Downey RJ, Gelfand SE, Begg CB,. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med. 2001; 345: 181-188.
28. Gourin CG, Forastiere AA, Sanguineti G, Koch WM, Marur S, Bristow RE,. Impact of surgeon and hospital volume on short-term outcomes and cost of laryngeal cancer surgical care. Laryngoscope. 2011; 121: 85-90.
29. Gourin CG, Forastiere AA, Sanguineti G, Marur S, Koch WM, Bristow RE,. Volume-based trends in laryngeal cancer surgery. Laryngoscope. 2011; 121: 77-84.